3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Multiple Myeloma
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Carcinoma, Non-Small-Cell Lung
2
Ulcer
1
Stomatitis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Philadelphia Chromosome
1
Ovarian Neoplasms
1
Neurofibromatosis 1
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Head and Neck Neoplasms
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Burkitt Lymphoma
1
Adenocarcinoma
1
Interventions
Paclitaxel
47
Carboplatin
38
liposomal doxorubicin
25
Bevacizumab
23
Gemcitabine
18
Topotecan
15
pembrolizumab
14
mirvetuximab soravtansine
11
rucaparib
8
niraparib
7
Cisplatin
7
1-dodecylpyridoxal
7
trebananib
6
Drug Therapy
6
130-nm albumin-bound paclitaxel
6
Nivolumab
5
Cyclophosphamide
5
cemiplimab
4
sarilumab
3
relacorilant
3
pazopanib
3
oregovomab
3
olaparib
3
Doxorubicin
3
Docetaxel
3
Albumin-Bound Paclitaxel
3
tocilizumab
2
seribantumab
2
phenoxodiol
2
pegfilgrastim
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Fallopian Tube Neoplasms
×
Acetaminophen
×
Clear all
NCT06824467
2026-05-29
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3
Recruiting
770 enrolled